Compare · ARGX vs VCEL
ARGX vs VCEL
Side-by-side comparison of argenx SE (ARGX) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $63.27B, about 28.6x VCEL ($2.21B).
- ARGX has been more active in the news (11 items in the past 4 weeks vs 2 for VCEL).
- ARGX has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- argenx SE
- Vericel Corporation
- Price
- -
- -
- Market cap
- $63.27B
- $2.21B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 11
- 2
- Recent ratings
- 25
- 11
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest ARGX
- argenx downgraded by Deutsche Bank
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- SEC Form 6-K filed by argenx SE
- Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
- Amendment: SEC Form SC TO-T/A filed by argenx SE
- argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
- SEC Form SC TO-T filed by argenx SE
- Guggenheim resumed coverage on argenx with a new price target
- SEC Form 6-K filed by argenx SE
Latest VCEL
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- Chief Operating Officer Halpin Michael exercised 10,000 shares at a strike of $16.66 and sold $468,400 worth of shares (10,000 units at $46.84) as part of a pre-agreed trading plan (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan exercised 4,500 shares at a strike of $31.51 and sold $220,050 worth of shares (4,500 units at $48.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
- Principal Accounting Officer Siegal Jonathan exercised 2,500 shares at a strike of $29.82 and sold $122,667 worth of shares (2,732 units at $44.90) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 886 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $223,750 worth of shares (5,000 units at $44.75) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 16,009 units (SEC Form 4)
- Chief Medical Officer Hopper Jonathan Mark sold $450,000 worth of shares (10,000 units at $45.00) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $29.82 (SEC Form 4)